Dose Finding At Breakthrough Speed: FDA Found A Role For Anecdotal Reports On Zykadia
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Review of Novartis’ lung cancer therapy highlights the difficulties of getting traditional dosing work done in the compressed development program of a “breakthrough” drug – and shows just how flexible the agency will be in gathering information for the accelerated programs.